Cosmos Health Inc. (COSM)
USD 0.45
(-2.91%)
USD 0.45
(-2.91%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.83 Million USD | -192.09% |
| 2022 | -7.47 Million USD | -64.87% |
| 2021 | -4.53 Million USD | -267.02% |
| 2020 | 2.71 Million USD | 12475.95% |
| 2019 | -21.93 Thousand USD | 98.21% |
| 2018 | -1.22 Million USD | 74.79% |
| 2017 | -4.87 Million USD | -2306.0% |
| 2016 | -202.5 Thousand USD | 54.23% |
| 2015 | -442.45 Thousand USD | -106.22% |
| 2014 | 7.11 Million USD | 2364.66% |
| 2013 | 288.71 Thousand USD | 63553.19% |
| 2012 | -455.00 USD | 99.73% |
| 2011 | -169.24 Thousand USD | 95.53% |
| 2010 | -3.78 Million USD | -82252.8% |
| 2009 | -4600.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.83 Million USD | 86.49% |
| 2024 Q2 | -2.5 Million USD | -36.27% |
| 2023 Q3 | -3.01 Million USD | -17.11% |
| 2023 FY | -21.83 Million USD | -192.09% |
| 2023 Q1 | -2.65 Million USD | 63.67% |
| 2023 Q2 | -2.57 Million USD | 2.82% |
| 2023 Q4 | -13.58 Million USD | -350.28% |
| 2022 Q1 | 242.25 Thousand USD | 147.38% |
| 2022 Q3 | -344.11 Thousand USD | -360.79% |
| 2022 Q4 | -7.29 Million USD | -2020.77% |
| 2022 FY | -7.47 Million USD | -64.87% |
| 2022 Q2 | -74.67 Thousand USD | -130.83% |
| 2021 Q2 | -1.37 Million USD | 20.49% |
| 2021 Q3 | -914.55 Thousand USD | 33.56% |
| 2021 Q4 | -511.28 Thousand USD | 44.09% |
| 2021 FY | -4.53 Million USD | -267.02% |
| 2021 Q1 | -1.73 Million USD | -509.81% |
| 2020 Q1 | 225.56 Thousand USD | -59.75% |
| 2020 Q4 | 422.41 Thousand USD | -60.89% |
| 2020 Q3 | 1.08 Million USD | 9.5% |
| 2020 FY | 2.71 Million USD | 12475.95% |
| 2020 Q2 | 986.31 Thousand USD | 337.27% |
| 2019 Q2 | -525.88 Thousand USD | -202.68% |
| 2019 Q4 | 560.38 Thousand USD | 580.76% |
| 2019 FY | -21.93 Thousand USD | 98.21% |
| 2019 Q1 | -173.74 Thousand USD | 83.32% |
| 2019 Q3 | -116.56 Thousand USD | 77.84% |
| 2018 Q2 | -78.78 Thousand USD | 47.32% |
| 2018 Q3 | 41.49 Thousand USD | 152.67% |
| 2018 Q4 | -1.04 Million USD | -2610.26% |
| 2018 FY | -1.22 Million USD | 74.79% |
| 2018 Q1 | -149.54 Thousand USD | 96.31% |
| 2017 Q1 | -1.98 Million USD | -4453.4% |
| 2017 FY | -4.87 Million USD | -2306.0% |
| 2017 Q4 | -4.05 Million USD | -24766.74% |
| 2017 Q3 | 16.44 Thousand USD | 102.06% |
| 2017 Q2 | -796.64 Thousand USD | 59.86% |
| 2016 Q2 | -86.93 Thousand USD | -111.95% |
| 2016 Q4 | -43.59 Thousand USD | -40.75% |
| 2016 Q3 | -30.96 Thousand USD | 64.38% |
| 2016 FY | -202.5 Thousand USD | 54.23% |
| 2016 Q1 | -41.01 Thousand USD | 76.32% |
| 2015 Q2 | -109.8 Thousand USD | -30.28% |
| 2015 Q1 | -84.28 Thousand USD | 65.5% |
| 2015 FY | -442.45 Thousand USD | -106.22% |
| 2015 Q4 | -173.22 Thousand USD | -130.5% |
| 2015 Q3 | -75.15 Thousand USD | 31.56% |
| 2014 Q2 | 1.06 Million USD | 50.58% |
| 2014 Q1 | 707.88 Thousand USD | -17.86% |
| 2014 Q3 | 5.58 Million USD | 424.09% |
| 2014 Q4 | -244.26 Thousand USD | -104.37% |
| 2014 FY | 7.11 Million USD | 2364.66% |
| 2013 Q2 | -43.84 Thousand USD | 24.47% |
| 2013 FY | 288.71 Thousand USD | 63553.19% |
| 2013 Q1 | -58.04 Thousand USD | 49.5% |
| 2013 Q3 | -79.34 Thousand USD | -80.98% |
| 2013 Q4 | 861.77 Thousand USD | 1186.16% |
| 2012 Q2 | -59.72 Thousand USD | -9.46% |
| 2012 Q1 | -54.56 Thousand USD | 2.41% |
| 2012 Q4 | -114.93 Thousand USD | 10.02% |
| 2012 Q3 | -127.72 Thousand USD | -113.85% |
| 2012 FY | -455.00 USD | 99.73% |
| 2011 Q3 | -160.38 Thousand USD | -161.17% |
| 2011 Q2 | -61.41 Thousand USD | 29.69% |
| 2011 Q4 | -55.91 Thousand USD | 65.14% |
| 2011 Q1 | -87.34 Thousand USD | -646.45% |
| 2011 FY | -169.24 Thousand USD | 95.53% |
| 2010 Q1 | 238.00 USD | 0.0% |
| 2010 FY | -3.78 Million USD | -82252.8% |
| 2010 Q2 | -3.71 Million USD | -1562742.44% |
| 2010 Q3 | -8783.00 USD | 99.76% |
| 2010 Q4 | -11.7 Thousand USD | -33.23% |
| 2009 FY | -4600.00 USD | 0.0% |
| 2009 Q4 | 238.00 USD | 100.61% |
| 2009 Q3 | -39.25 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 146.478% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -44.558% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 113.076% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -8.884% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 85.966% |
| Cronos Group Inc. | -81.37 Million USD | 73.172% |
| Incannex Healthcare Limited | -30.04 Million USD | 27.329% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 44.241% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 333.964% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -360.893% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -356.214% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -356.214% |
| SCYNEXIS, Inc. | 72.66 Million USD | 130.042% |
| Safety Shot Inc | -12.18 Million USD | -79.177% |
| Theratechnologies Inc. | -10.62 Million USD | -105.432% |
| Alpha Teknova, Inc. | -35.56 Million USD | 38.613% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -519.014% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 124.9% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -364.395% |
| Dynavax Technologies Corporation | -37.02 Million USD | 41.041% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 110.444% |
| Radius Health, Inc. | -3.92 Million USD | -456.209% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -767.966% |
| Alvotech | -354.86 Million USD | 93.848% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 86.302% |
| SIGA Technologies, Inc. | 83.62 Million USD | 126.107% |
| Shineco, Inc. | -17.06 Million USD | -27.923% |
| Silver Spike Investment Corp. | 7.34 Million USD | 397.424% |
| Journey Medical Corporation | -2.07 Million USD | -953.122% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -60.319% |
| Embecta Corp. | 221.5 Million USD | 109.856% |
| Harrow Health, Inc. | 580 Thousand USD | 3864.003% |
| Procaps Group, S.A. | 38.97 Million USD | 156.016% |
| Biofrontera Inc. | -22.67 Million USD | 3.73% |
| DURECT Corporation | -36.88 Million USD | 40.811% |
| PainReform Ltd. | -9.58 Million USD | -127.788% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -314.333% |
| OptiNose, Inc. | -22.74 Million USD | 4.03% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 272.825% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 274.301% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -251.503% |
| ProPhase Labs, Inc. | -21.61 Million USD | -1.01% |
| Phibro Animal Health Corporation | 53.31 Million USD | 140.948% |
| Procaps Group S.A. | 52.32 Million USD | 141.723% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -156.145% |
| Viatris Inc. | 766.2 Million USD | 102.849% |
| Rockwell Medical, Inc. | -6.67 Million USD | -227.305% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -315.516% |
| Tilray Brands, Inc. | -174.74 Million USD | 87.507% |
| PetIQ, Inc. | 60.01 Million USD | 136.376% |
| Talphera, Inc. | -16.88 Million USD | -29.263% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 108.701% |
| Alimera Sciences, Inc. | -1.47 Million USD | -1384.107% |
| Assertio Holdings, Inc. | -243.53 Million USD | 91.036% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -270.499% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 84.163% |
| Hempacco Co., Inc. | -8.81 Million USD | -147.736% |
| Alvotech | -354.86 Million USD | 93.848% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 105.987% |
| Kamada Ltd. | 10.06 Million USD | 316.924% |
| Currenc Group, Inc. | -6.64 Million USD | -228.497% |
| Indivior PLC | -4 Million USD | -445.78% |
| Evoke Pharma, Inc. | -7.43 Million USD | -193.79% |
| Flora Growth Corp. | -50.35 Million USD | 56.645% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -8.884% |
| Evolus, Inc. | -49.23 Million USD | 55.657% |
| HUTCHMED (China) Limited | 18.37 Million USD | 218.809% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 111.083% |
| Akanda Corp. | -10.05 Million USD | -117.196% |